View Clinical Trial (Medical Research Study)
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers
| City: |
|
Lakewood |
| State: |
|
California |
| Zip Code: |
|
90712 |
| Conditions: |
|
Asthma |
| Purpose: |
|
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory
airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to
severe persistent expiratory airflow obstruction. Treatment will include inhaled
corticosteroids and long acting beta2agonists. The investigators are interested in
determining whether the large and/or small airways are the predominant site of airflow
limitation. The investigators are also interested in determining whether intrinsic small
airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow
limitation. The investigators are also interested to evaluate the role of varying doses of
inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric
oxide as surrogate markers of inflammation. For comparison purposes, spirometry and
measurements of exhaled nitric oxide will also be obtained if possible during a naturally
occurring exacerbation of asthma.
|
| Study Summary: |
|
In addition we will also obtain above studies in asthmatics during naturally occuring
exacerbation of asthma and following treatment. If available, results of lung function
studies including measurements of lung elastic recoil will be compared to pathologic
analyses of formalin fixed, air inflated lungs obtained at autopsy in asthmatics who die
from asthma related or non-asthma related death. This kind of lung structure-function study
will provide potential mechanism(s) to explain the loss of lung elastic recoil in acute and
chronic asthmatics who are non-smokers. We will also obtain voxel quantification of high
resolution thin section CT of lung obtained without IV contrast. Also, we will use
fiberoptic bronchoscopy to obtain optical coherence tomography in stable asthmatics with
mild to moderate to severe expiratory airflow limitation to assess integrity of the lung
parenchyma.
|
| Criteria: |
|
Inclusion Criteria:
- Current non-smoking (<10 pack yr smoking history)
- Stable, treated asthmatics
- Age 10-80 yr
- post 180ug albuterol by MDI: FEV 1/FVC < 70% and FEV 1 <80% predicted
Exclusion Criteria:
- Pregnancy
|
| NCT ID: |
|
NCT01225913 |
| Primary Contact: |
|
Principal Investigator
Arthur F Gelb, MD
Arthur F Gelb Medical Corporation
Arthur F Gelb, MD
Phone: 562-633-2204
Email: afgelb@msn.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Lakewood, California 90712
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|